News & Events

Press Releases

September 5 2006

European Commission Grants Orphan Medicinal Product Designation for vasopharm's drug candidate VAS203

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, announced today that the European Commission has granted orphan medicinal product status for its drug candidate VAS203 for the treatment of traumatic brain injury. This designation is based on a recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA). VAS203, a NO Synthase modulator, is developed exclusively for the acute indication of closed head injury.

Read on Download PDF